EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Improved Screening of Monoclonal Gammopathy Patients by MALDI-TOF Mass Spectrometry

Lukáš Pečinka, Monika Vlachová, Lukáš Moráň, Jana Gregorová, Volodymyr Porokh, Petra Kovačovicová, Martina Almáši iD, Luděk Pour, Martin Štork, Josef Havel iD, Sabina Ševčíková, Petr Vaňhara iD

Journal of the American Society for Mass Spectrometry · 2023

DOI: 10.1021/jasms.3c00166 ↗

At a glance

Journal article in Journal of the American Society for Mass Spectrometry, 2023. Written by Lukáš Pečinka and 11 co-authors. Institution: Department of Chemistry, Faculty of Science, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic. Major MEDLINE topics: Multiple Myeloma, Leukemia, Plasma Cell, Paraproteinemias. Cited 5 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY 4.0). Funded by: European Commission, Ministerstvo Zdravotnictv? Cesk? Republiky, Masarykova Univerzita.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Monoclonal gammopathies are a group of blood diseases characterized by presence of abnormal immunoglobulins in peripheral blood and/or urine of patients. Multiple myeloma and plasma cell leukemia are monoclonal gammopathies with unclear etiology, caused by malignant transformation of bone marrow plasma cells. Mass spectrometry with matrix-assisted laser desorption/ionization and time-of-flight detection is commonly used for investigation of the peptidome and small proteome of blood plasma with high accuracy, robustness, and cost-effectivity. In addition, mass spectrometry coupled with advanced statistics can be used for molecular profiling, classification, and diagnosis of liquid biopsies and tissue specimens in various malignancies. Despite the fact there have been fully optimized protocols for mass spectrometry of normal blood plasma available for decades, in monoclonal gammopathy patients, the massive alterations of biophysical and biochemical parameters of peripheral blood plasma often limit the mass spectrometry measurements. In this paper, we present a new two-step extraction protocol and demonstrated the enhanced resolution and intensity (>50×) of mass spectra obtained from extracts of peripheral blood plasma from monoclonal gammopathy patients. When coupled with advanced statistics and machine learning, the mass spectra profiles enabled the direct identification, classification, and discrimination of multiple myeloma and plasma cell leukemia patients with high accuracy and precision. A model based on PLS-DA achieved the best performance with 71.5% accuracy (95% confidence interval, CI = 57.1-83.3%) when the 10× repeated 5-fold CV was performed. In summary, the two-step extraction protocol improved the analysis of monoclonal gammopathy peripheral blood plasma samples by mass spectrometry and provided a tool for addressing the complex molecular etiology of monoclonal gammopathies.

Subjects

MeSH terms (MEDLINE)

Multiple MyelomaLeukemia, Plasma CellParaproteinemiasHumansSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationPlasma

Author keywords

MALDI-TOF mass spectrometryfingerprintingmachine learningmolecular profilingmonoclonal gammopathymultiple myelomapartial least-squares-discriminant analysisplasma cell leukemiaprincipal component analysis

Authors and institutions

  • Department of Chemistry, Faculty of Science, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
  • International Clinical Research Center, St. Anne's University Hospital Brno, Pekařská 53, 656 91 Brno, Czech Republic.
  • Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, Kamenice 3, 625 00 Brno, Czech Republic.
  • Department of Histology and Embryology, Faculty of Medicine, Masaryk University, Kamenice 3, 625 00 Brno, Czech Republic.
  • Research Centre for Applied Molecular Oncology (RECAMO), Masaryk Memorial Cancer Institute, Žlutý kopec 7, 602 00 Brno, Czech Republic.
  • Department of Clinical Hematology, University Hospital Brno, Jihlavská 20, 625 00 Brno, Czech Republic.

ORCID profiles: Martina Almáši, Josef Havel, Petr Vaňhara

Funding

  • European Commission
  • Ministerstvo Zdravotnictv? Cesk? Republiky
  • Masarykova Univerzita

Cite

APA

Pečinka, L., Vlachová, M., Moráň, L., Gregorová, J., Porokh, V., Kovačovicová, P., Almáši, M., Pour, L., Štork, M., Havel, J., Ševčíková, S., & Vaňhara, P. (2023). Improved Screening of Monoclonal Gammopathy Patients by MALDI-TOF Mass Spectrometry. Journal of the American Society for Mass Spectrometry. https://doi.org/10.1021/jasms.3c00166

Vancouver

Pečinka L, Vlachová M, Moráň L, Gregorová J, Porokh V, Kovačovicová P, et al. Improved Screening of Monoclonal Gammopathy Patients by MALDI-TOF Mass Spectrometry. Journal of the American Society for Mass Spectrometry. 2023. doi:10.1021/jasms.3c00166

BibTeX
@article{Peinka2023,
  author = {Pečinka, Lukáš and Vlachová, Monika and Moráň, Lukáš and Gregorová, Jana and Porokh, Volodymyr and Kovačovicová, Petra and Almáši, Martina and Pour, Luděk and Štork, Martin and Havel, Josef and Ševčíková, Sabina and Vaňhara, Petr},
  title = {Improved Screening of Monoclonal Gammopathy Patients by MALDI-TOF Mass Spectrometry},
  journal = {Journal of the American Society for Mass Spectrometry},
  year = {2023},
  doi = {10.1021/jasms.3c00166}
}
Start for free →